Sanara MedTech achieved net revenue of $26.3 million in Q4 2024, representing a 49% increase compared to the prior year. Gross profit rose to $24.1 million with a strong margin of 91%. Despite these gains, the company recorded a net loss of $1.7 million, influenced by higher SG&A and R&D costs, as well as increased interest expenses.
Q4 2024 net revenue rose 49% year-over-year to $26.3 million.
Gross profit reached $24.1 million, with a 91% gross margin.
Net loss widened to $1.7 million, impacted by increased SG&A, R&D, and interest expenses.
Soft tissue repair products sales increased 56%, driving overall revenue growth.
Sanara MedTech plans to continue investing in its Tissue Health Plus platform in 2025, with a pilot program launch expected in Q2, while focusing on profitability improvements in the Sanara Surgical segment.
Visualization of income flow from segment revenue to net income